Data also look at the effect of OFEV treatment on patients with mild lung function impairment and characteristics consistent with early disease presentation, which is representative of those seen in clinical practice.”Īdditional details on the OFEV presentations are available here by searching the abstract numbers listed below. “The data being presented at the American Thoracic Society International Conference provide additional insights into OFEV, including the safety and efficacy beyond 52 weeks. “Boehringer Ingelheim continues to research the safety and efficacy of OFEV to improve the understanding of IPF and the role that medicine can play in treating it,” said Danny McBryan, M.D., vice president, Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. Early diagnosis and proper care and treatment are critical to helping people with their condition. It affects as many as 132,000 Americans, most commonly men over the age of 65. IPF is a rare and serious lung disease that causes permanent scarring of the lungs. These new findings underscore the need for early detection and treatment.”
“Additionally, results from other analyses show a consistent effect in patients who had mild lung function impairment or lacked extensive lung scarring, such as honeycombing in high-resolution CT scans. “The long-term safety studies are important because people with IPF may be on therapy for an extended period,” said lead study author Luca Richeldi, M.D., Ph.D., Professor of Respiratory Medicine, Chair of Interstitial Lung Disease, University of Southampton, Honorary Consultant Physician, University Hospital Southampton. The findings were presented yesterday at the American Thoracic Society 2015 International Conference in Denver. Boehringer Ingelheim announced new data and analyses that provide further evidence to support the efficacy, safety and tolerability of OFEV® (nintedanib) capsules in patients with idiopathic pulmonary fibrosis (IPF).
0 kommentar(er)
